Risk Prediction Models for Myocardial Dysfunction and Heart Failure in Patients with Current or Prior Cancer
E C van Dalen1, J M Leerink1,2, L C M Kremer1,3
1Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584CS, Utrecht, The Netherlands.
Current Oncology Reports
|February 14, 2023
Summary
Cancer treatments can harm the heart. Risk prediction models help identify patients at risk for heart problems, but their accuracy varies. Improving these models is crucial for guiding patient care.
Area of Science:
- Cardiology
- Oncology
- Medical Informatics
Background:
- Cancer patients face risks of heart dysfunction and failure due to treatments.
- Risk prediction models are essential for stratifying patients based on cardiac event risk.
Purpose of the Study:
- To review the current role and impact of risk prediction models in managing cancer treatment-related cardiac dysfunction.
- To highlight the variability in model performance and the need for improved methodologies.
Main Methods:
- Review of existing literature on risk prediction models for cancer therapy-induced cardiotoxicity.
- Analysis of the reported performance and limitations of current models.
Main Results:
- A wide range of predictive abilities exists among developed risk models, from poor to strong.
- Methodological limitations and lack of reporting hinder a complete assessment of model accuracy.
Conclusions:
- Risk prediction models hold significant potential for identifying at-risk cancer patients.
- Enhancing the quality and reporting of these models is vital for informing clinical decisions and patient care regarding cardiac events.
More Related Videos
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
319
05:16Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
163
Related Concept Videos
01:27Heart Failure I: Introduction
30
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
30
01:30Heart Failure IV: Classification and Diagnostic Evaluation
24
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
24
01:21Cancer Survival Analysis
408
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
408
01:17Pathophysiology of Heart Failure
1.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.7K
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
219
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
219
01:30Cardiomyopathy II: Dilated Cardiomyopathy
15
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
15